Page 3 - Patrickr Oneil News Today

AtonRa Partners reduced its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) by 21.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,875 shares of the company’s stock after selling 3,753 shares during the period. AtonRa Partners’ holdings in […]

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) has received a consensus rating of “Hold” from the thirteen brokerages that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating on the company. The average […]

Wall Street analysts forecast that Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) will post sales of $145.04 million for the current fiscal quarter, according to Zacks. Eight analysts have made estimates for Ionis Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $107.00 million and the highest estimate coming in at $193.90 million. Ionis […]

Wall Street brokerages forecast that Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) will report earnings per share (EPS) of ($0.62) for the current fiscal quarter, according to Zacks. Eight analysts have made estimates for Ionis Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.77) and the highest estimate coming in at ($0.31). Ionis […]

Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) have been assigned an average recommendation of “Hold” from the twelve brokerages that are currently covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating […]

StockNews.com upgraded shares of Ionis Pharmaceuticals (NASDAQ:IONS – Get Rating) from a hold rating to a buy rating in a research report report published on Thursday morning. Several other equities research analysts also recently weighed in on IONS. Bank of America downgraded shares of Ionis Pharmaceuticals from a buy rating to an underperform rating and […]

Ionis Pharmaceuticals (NASDAQ:IONS – Get Rating) was upgraded by stock analysts at TheStreet from a “d+” rating to a “c-” rating in a note issued to investors on Wednesday, TheStreetRatingsTable reports. A number of other brokerages have also recently weighed in on IONS. Guggenheim started coverage on shares of Ionis Pharmaceuticals in a research note […]

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) – Investment analysts at Oppenheimer decreased their Q1 2022 earnings per share estimates for shares of Ionis Pharmaceuticals in a research note issued to investors on Monday, April 18th. Oppenheimer analyst K. Degeeter now anticipates that the company will post earnings of ($0.75) per share for the quarter, […]